Stabilizes microtubules and inhibits the reorganization needed for mitotic division and other cellular functions.

Recommended dose is 260 mg/m² administered intravenously over 30 minutes every three weeks.

Indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within six months of adjuvant therapy. An anthracycline should have been part of the prior chemotherapy. This chemotherapy agent is not interchangeable with paclitaxel in its approved indications.

Dose-dependent and dose-limiting myelosuppression (especially neutropenia), sensory neuropathy, myalgia, arthralgia, nausea, diarrhea, alopecia (complete hair loss), injection site reactions, vesicant reactions, and ECG abnormalities.

Drug is free of solvents; therefore, no premedication is required to prevent hypersensitivity reactions. No inline filter or use of polyvinyl chloride tubing is required.

Drug is composed of albumin, which brings a remote risk of viral disease transmission.

Consider dose reduction by about 20% for grade 3 sensory neuropathy; resume treatment with reduced dose when neuropathy improves to grade 1 or 2.

Do not use in patients with baseline neutrophil count < 1,500 cells/mm3 and/or platelet count < 100,000 cells/mm³.